20/20 Biolabs, Inc. Balance Sheet
AIDX|1 years of annual SEC 10-K data (FY2025-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity. All figures from audited SEC 10-K filings.
20/20 Biolabs, Inc. had $4M in total assets with negative shareholders' equity of $19,225 as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -8.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 |
|---|---|
| Cash & Equivalents | $1.0M |
| Accounts Receivable | $200.0K |
| Inventory | $116.2K |
| Current Assets | $1.5M |
| PP&E (Net) | $56.7K |
| Total Assets | $4.1M |
| Current Liabilities | $2.5M |
| Shareholders' Equity | -$19.2K |